Benedict Cross, Chief Technology Officer, discusses the changing landscape of drug discovery, and the potential of new multi-modal screening tools such as PROTEINi, the basis for PhoreMost’s SITESEEKER® platform.
For an area of research as important and impactful as drug discovery, it is surprising how often efforts are directed by short-term trends. We have seen an abundance in new tools and platforms over recent years, including hugely influential CRISPR-based technologies. How should these new technologies be used, to enable progression from target discovery to the clinic?
Read the full article in the Spring issue of DDW at:
ddw-online.com/target-discovery-and-drug-development-what-comes-after-crispr-1281-202004